Lu Yu
About Lu Yu
Lu Yu serves as the Vice President and Head of Clinical Development at AffaMed Therapeutics, where he has worked since 2021. He has extensive experience in clinical trial applications and drug development across various therapeutic areas, particularly in neuroscience and cardiovascular medicine.
Work at AffaMed Therapeutics
Lu Yu has been serving as the Vice President and Head of Clinical Development at AffaMed Therapeutics since 2021. In this role, he oversees clinical development initiatives and is responsible for leading Clinical Trial Applications (CTA) and New Drug Application (NDA) submissions and approvals. His leadership in clinical development is pivotal for the company's strategic direction in bringing innovative therapies to market.
Education and Expertise
Lu Yu earned his Ph.D. in Neuroscience from the Neuroscience Research Center of Peking University, where he studied from 2002 to 2007. Prior to that, he completed his bachelor's degree in Clinical Medicine at the Health Science Center of Peking University from 1997 to 2002. His educational background provides a strong foundation for his expertise in drug development strategies, particularly in Neuroscience, Cardiovascular and Metabolism, Immune and Respiratory Diseases, and Pulmonary Arterial Hypertension.
Background
Before joining AffaMed Therapeutics, Lu Yu worked at The Janssen Pharmaceutical Companies of Johnson & Johnson for 14 years, from 2007 to 2021, in Beijing. He held the position of Director, NS/CVM/PAH TA Lead within Clinical Development. His extensive experience in a leading pharmaceutical company has equipped him with a comprehensive understanding of the clinical development landscape.
Achievements
Lu Yu has a track record of leading several Clinical Trial Applications (CTA) and New Drug Application (NDA) submissions and approvals throughout his career. He has over 12 years of experience in people leadership, focusing on coaching physicians and cross-functional team members. His involvement spans every step of end-to-end drug development, including portfolio and program development strategies.
Advocacy for Drug Innovation in China
Lu Yu advocates for the simultaneous launch of innovative drugs in China. He aims to increase the approval of domestic innovative new drugs, contributing to the advancement of healthcare solutions within the country. His efforts reflect a commitment to enhancing the pharmaceutical landscape and improving patient access to new therapies.